(Q37686724)

22 August 2017

1 reference

title

Current strategies and recent advances in the therapy of hypercholesterolemia (English)

1 reference

22 August 2017

0 references

E Windler

1

1 reference

22 August 2017

B-Chr Zyriax

2

1 reference

22 August 2017

Chr Bamberger

3

1 reference

22 August 2017

F Rinninger

4

1 reference

22 August 2017

F-U Beil

5

1 reference

22 August 2017

language of work or name

1 reference

1 December 2009

1 reference

Atherosclerosis. Supplements

22 August 2017

1 reference

22 August 2017

10

1 reference

22 August 2017

5

1 reference

22 August 2017

1-4

1 reference

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

22 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2900065-8

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2900065-8

7 January 2021

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2900065-8

7 January 2021

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2900065-8

7 January 2021

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2900065-8

7 January 2021

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2900065-8

7 January 2021

Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2900065-8

7 January 2021

Continuous dose-response relationship of the LDL-cholesterol-lowering effect of phytosterol intake.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2900065-8

7 January 2021

Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2900065-8

7 January 2021

Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2900065-8

7 January 2021

Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2900065-8

7 January 2021

Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2900065-8

7 January 2021

Effects of torcetrapib in patients at high risk for coronary events

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2900065-8

7 January 2021

CETP inhibitors to increase HDL cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2900065-8

7 January 2021

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2900065-8

7 January 2021

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2900065-8

7 January 2021

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2900065-8

7 January 2021

Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2900065-8

7 January 2021

Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2900065-8

7 January 2021

Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2900065-8

7 January 2021

10.1016/S1567-5688(09)00065-8

Identifiers

DOI

1 reference

22 August 2017

1 reference